期刊文献+

CRISPR靶向切割毒力因子tcdB基因抑制致病艰难梭菌生长 被引量:1

CRISPR targeting and incising toxin gene tcdB inhibits the growth of disease-causing Clostridioide difficile
下载PDF
导出
摘要 目的应用CRISPR/Cas9系统对艰难梭菌主要毒力因子tcdB基因进行切割,达到特异性抑制致病艰难梭菌生长的效果。方法在线设计针对tcdB的sgRNA,分别将sgRNA与Cas9单独或共同作用于tcdB基因扩增产物,验证体外切割效能;分别将穿膜肽(CPP)-sgRNA或单独的sgRNA与CPP-Cas9单独或共同作用于产毒艰难梭菌,通过监测菌液A值和菌落计数,观察对细菌生长的抑制效果。同样的方法处理肠道其他细菌,验证特异性。结果sgRNA和Cas9共同作用可把tcdB扩增产物有效切割,而单独加入sgRNA或Cas9均无切割作用;单独加入CPP-sgRNA、CPP-Cas9、CPP对细菌生长没有影响;CPP-sgRNA与CPP-Cas9共同作用,无细菌生长;单独sgRNA与CPP-Cas9共同作用,细菌生长轻度受抑。用同样的方法将CPP-sgRNA+CPP-Cas9处理肠道其他细菌后,菌液A值和菌落计数与空白对照无差别。结论建立的针对tcdB的sgRNA与Cas9混合可在体外高效切割tcdB基因,抑制细菌生长;CPP可提高sgRNA转染进入细菌的效率。 Objective The CRISPR/Cas9 system was used to cleave the major virulence factor tcdB gene of Clostridioide difficile to achieve specific inhibition of the growth of disease-causing Clostridioide difficile.Methods The sgRNA targeting tcdB was designed online,and sgRNA and Cas9 were separately or co-operated on the tcdB gene amplification product to verify the cleavage efficiency in vitro.The CPP-sgRNA or the sgRNA alone and CPP-Cas9 were used alone or in combination to the toxin-producing Clostridioide difficile,the inhibition of bacterial growth was observed by monitoring the A value of the bacterial liquid and the colony count.The same method was used to treat other bacteria in the intestine for specific verification.Results The combination of sgRNA and Cas9 can effectively cleave the tcdB amplification product,while sgRNA or Cas9 alone has no cleavage effect.In contrast to the untreated group,the groups in which CPP-sgRNA,CPP-Cas9,and CPP were added alone had no effect on bacterial growth;the group in which the CPP-sgRNA interacted with CPP-Cas9 has no bacterial growth;sgRNA and CPP-Cas9 Together,it has a slightly inhibited effect on bacterial growth.After treated used CPP-sgRNA+CPP-Cas9 by the same method,there was no difference of the A value and the colony count of the other intestinal bacteria from the blank.Conclusion The sgRNA targeting tcdB combined with Cas9 can efficiently cleave the tcdB gene and inhibit bacterial growthin in vitro.CPP can improve the efficiency of sgRNA transfecting into bacteria.
作者 张大炜 夏云 赵靳鑫 陈盈竹 邹家齐 严佳 杨蜜 ZHANG Dawei;XIA Yun;ZHAO Jinxin;CHEN Yinzhu;ZOU Jiaqi;YAN Jia;YANG Mi(Department of Laboratory Medicine,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
出处 《国际检验医学杂志》 CAS 2019年第24期3036-3040,共5页 International Journal of Laboratory Medicine
关键词 CRISPR/Cas9 艰难梭菌 tcdB基因 穿膜肽 CRISPR/Cas9 Clostridioide difficile tcdB gene penetrating peptide
  • 相关文献

参考文献3

二级参考文献41

  • 1Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparisonof the burdens of hospital-onset, healthcare facility-associatedClostridium difficile Infection and of healthcare-associatedinfection due to methicillin-resistant Staphylococcus aureus incommunity hospitals. Infect Control Hosp Epidemiol 2011; 32:387-390 [PMID: 21460491 DOI: 10.1086/659156].
  • 2Honda H, Dubberke ER. The changing epidemiology ofClostridium difficile infection. Curr Opin Gastroenterol 2014; 30:54-62 [PMID: 24285002 DOI: 10.1097/MOG.0000000000000018].
  • 3Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factorsfor recurrence, complications and mortality in Clostridium difficileinfection: a systematic review. PLoS One 2014; 9: e98400 [PMID:24897375 DOI: 10.1371/journal.pone.0098400].
  • 4Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. Theroles of Clostridium difficile and norovirus among gastroenteritisassociateddeaths in the United States, 1999-2007. Clin Infect Dis2012; 55: 216-223 [PMID: 22491338 DOI: 10.1093/cid/cis386].
  • 5Dubberke ER, Butler AM, Reske KA, Agniel D, Olsen MA, D'Angelo G, McDonald LC, Fraser VJ. Attributable outcomes ofendemic Clostridium difficile-associated disease in nonsurgicalpatients. Emerg Infect Dis 2008; 14: 1031-1038 [PMID: 18598621DOI: 10.3201/eid1407.070867].
  • 6Dubberke ER, Olsen MA. Burden of Clostridium difficile onthe healthcare system. Clin Infect Dis 2012; 55 Suppl 2: S88-S92[PMID: 22752870 DOI: 10.1093/cid/cis335].
  • 7Centers for Disease Control and Prevention (CDC). Vital signs:preventing Clostridium difficile infections. MMWR Morb MortalWkly Rep 2012; 61: 157-162 [PMID: 22398844].
  • 8Campbell RJ, Giljahn L, Machesky K, Cibulskas-White K, LaneLM, Porter K, Paulson JO, Smith FW, McDonald LC. Clostridiumdifficile infection in Ohio hospitals and nursing homes during2006. Infect Control Hosp Epidemiol 2009; 30: 526-533 [PMID:19419272 DOI: 10.1086/597507].
  • 9Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, ForgetK, Pépin K, Chouinard D. Clostridium difficile-associated diarrheain a region of Quebec from 1991 to 2003: a changing pattern ofdisease severity. CMAJ 2004; 171: 466-472 [PMID: 15337727].
  • 10Dudeck MA, Weiner LM , Malpiedi PJ, Edwards JR, PetersonKD. Sievert DM Risk Adjustment for Healthcare Facility-OnsetC. difficile and MRSA Bacteremia Laboratory-identified EventReporting in NHSN. Available from: URL: http://www.cdc.gov/nhsn/pdfs/mrsa-cdi/RiskAdjustment-MRSA-CDI.pdf.

共引文献140

同被引文献30

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部